**Important Facts About**

**SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED)**

**WHAT IS SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED)?**
- SHINGRIX is an FDA-approved vaccine for the prevention of shingles (herpes zoster):
  - In adults 50 years and older
  - In adults 18 years and older who are or will be at increased risk of shingles due to being immunocompromised by known disease or therapy
- SHINGRIX is not used to prevent chickenpox

**WHO SHOULD NOT GET SHINGRIX?**
- You should not receive SHINGRIX if you are allergic to any of its ingredients or had an allergic reaction to a previous dose of SHINGRIX

**WHAT ARE THE POTENTIAL SIDE EFFECTS?**
- An increased risk of Guillain–Barré syndrome (severe muscle weakness) was observed after vaccination with SHINGRIX
- Fainting can happen after getting injectable vaccines, including SHINGRIX. Precautions should be taken to avoid falling and injury due to fainting
- The most common side effects are pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach
- More people experienced fever and shivering when SHINGRIX was given with PNEUMOVAX 23

**WHAT IS SHINGLES AND WHAT CAUSES IT?**
- Shingles, also known as herpes zoster, is a painful skin rash
- Shingles is caused by the same virus that causes chickenpox. 99% of people 50 years and older carry this virus. After a person recovers from chickenpox, the virus stays inactive in the body. As you age, your immune system starts to naturally decline, increasing your risk of the virus reactivating and causing shingles. 1 out of 3 people will get shingles in their lifetime

**HOW DOES SHINGRIX WORK?**
- SHINGRIX is a shingles vaccine that works to boost your body’s protection against shingles

**HOW IS SHINGRIX GIVEN?**
- SHINGRIX is given as a 2-dose vaccine series (0.5 mL each, given in the muscle of the upper arm). It is important to complete the 2-dose series
  - In adults 50 years and older the second dose should be given between 2 and 6 months after the first dose
  - In adults 18 years and older who are or will be immunocompromised due to disease or medication and might benefit from a shorter vaccination schedule, the second dose can be administered 1 to 2 months later

**ADDITIONAL IMPORTANT INFORMATION**
- SHINGRIX was not studied in pregnant or nursing women. Tell your healthcare provider if you are pregnant, plan to become pregnant, or are breastfeeding
- Vaccination with SHINGRIX may not protect all individuals
- Ask your healthcare provider about the risks and benefits of SHINGRIX. Only a healthcare provider can decide if SHINGRIX is right for you

**NEED MORE INFORMATION?**
- This is only a summary of important information
- To learn more about SHINGRIX, talk to your doctor, pharmacist, or other healthcare provider
- Visit SHINGRIX.com or call 1-800-772-9292 for more information

*PNEUMOVAX 23 is a trademark owned by Merck & Co., Inc. SHINGRIX is a trademark owned by or licensed to the GSK group of companies.*